Search clinical trials for: dry powder inahler

Total 4917 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Asthma

United States, Georgia, Hungary, Russian Federation, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

Asthma

United States, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients (NEXThaler)

COPD

United Kingdom
Theravance Biopharma
GlaxoSmithKline; Hammersmith Medicines Research

Completed

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Orion Corporation, Orion Pharma

Terminated

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway (BufoSwitch)

Asthma | COPD

Norway
Liquidia Technologies, Inc.
FGK Clinical Research GmbH

Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Pulmonary Arterial Hypertension

France, Germany
Pharmanex

Completed

Functional Test for a Drink Powder Alone and Combined Use With a Cosmetic Apparatus

Skin Elasticity | Beauty Drink Powder | Cosmetic Apparatus on Skin | Skin Dryness | Skin Moisture | Skin Evenness | Skin Firmness

China
GB002, Inc., a wholly owned subsidiary of Gossamer...

Completed

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, United Kingdom
Liquidia Technologies, Inc.
Nuventra, Inc.

Active, not recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Primary Pulmonary Hypertension

United States
Wake Forest University Health Sciences

Terminated

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

COPD | COPD Exacerbation

United States
Wageningen University and Research
The Protein Brewery

Completed

Digestibility of Fermotein™ (MyDi)

Digestive System

Netherlands
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (TRI-D)

Chronic Obstructive Pulmonary Disease

Bulgaria
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

Asthma

United States, Canada, Germany, Spain, Netherlands, Italy, United Kingdom
GlaxoSmithKline

Completed

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

Asthma

Canada, United States
University of Oxford

Terminated

STerOids in COVID-19 Study (STOIC)

Coronavirus Infection

United Kingdom
Novartis

Completed

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

Asthma

Canada
Aclaris Therapeutics, Inc.

Completed

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
University Medical Center Groningen

Completed

Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers

Covid19

Netherlands
Liquidia Technologies, Inc.
Nuventra, Inc.

Completed

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)

Primary Pulmonary Hypertension

United States
GlaxoSmithKline

Completed

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Pulmonary Disease, Chronic Obstructive

Netherlands, United Kingdom
GlaxoSmithKline

Completed

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Asthma

Poland, Romania, Russian Federation, United States, Canada
National Hepatology & Tropical Medicine Research...

Completed

Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome

Hepato-Renal Syndrome

Egypt
Cipla Ltd.

Completed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Bronchial Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
Chiesi Farmaceutici S.p.A.

Completed

Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD (GlycoNEXT)

Chronic Obstructive Pulmonary Disease (COPD)

Czechia, Germany, Hungary, Romania
Gary L. Pierce

Completed

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

COPD

United States
GlaxoSmithKline

Completed

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Pulmonary Disease, Chronic Obstructive

China, Korea, Republic of
Neutec Ar-Ge San ve Tic A.Ş

Completed

Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD (COPD)

Copd

Turkey
GB002, Inc., a wholly owned subsidiary of Gossamer...
Worldwide Clinical Trials; Pulmokine Inc.

Completed

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Safety Issues

United States
Glo Science, Inc.
Arizona School of Dentistry & Oral Health, A. T. Still University

Completed

Efficacy of Teeth Whitening Product Offerings in Adults

Tooth Discoloration

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Asthma

Germany
GlaxoSmithKline

Completed

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Eli Lilly and Company
Locemia Solutions ULC

Completed

Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia (AMG102)

Hypoglycemia

Canada
University of California, Los Angeles

Completed

Comparing the Effect of Whey and Soy Protein on the Absorption of Pomegranate Polyphenols in the Human Body

Healthy

United States
University of Wisconsin, Madison
Mayday Fund

Terminated

Vitamin D for Painful Nocturnal Leg Cramps

Leg Cramps, Nocturnal

United States
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
GlaxoSmithKline

Completed

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, South Africa
GlaxoSmithKline

Completed

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Asthma

United States
GlaxoSmithKline

Completed

A Clinical Trial to Study the Impact of a Nutritional Beverage on Tests of Memory in Healthy Preschool Age Children

Cognition

India
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis (DAS181)

Bronchiectasis | Asthma

United States
GlaxoSmithKline

Withdrawn

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Asthma
University of Tennessee Graduate School of Medicine
Mylan Specialty L.P.

Completed

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

COPD Exacerbation

United States
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
AstraZeneca
Parexel

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Chronic Obstructive Pulmonary Disease

United Kingdom

3

Subscribe